保乳治疗后切缘小于2 mm与阴性切缘的10年局部复发和乳腺癌死亡率风险无显著差异
该研究基于2001至2011年人群队列的10,863例接受保乳手术和全乳放疗的浸润性乳腺癌女性,按切缘状态分为阴性(≥2 mm)、close(<2 mm)和阳性三组,比较10年局部复发和乳腺癌特异性生存。结果显示close切缘与阴性切缘在局部复发和BCSS上无显著差异,支持经仔细选择的close切缘病例可不再次切除而直接辅助放疗。
要点
- close切缘(<2 mm)与阴性切缘的10年局部复发累积发生率分别为2.0%和1.8%,差异无统计学意义(P=.759)。
- 多因素分析中close切缘与阴性切缘相比局部复发风险比为1.25(95%CI 0.79-1.97,P=.350),无显著增加。
- 匹配分析显示close切缘与阴性切缘的局部复发(P=.114)和BCSS(P=.100)均相似。
核心结论
- 在该人群中,经选择的close或阳性切缘病例的局部复发和BCSS与阴性切缘病例相似,支持经仔细选择的close切缘病例可不再次切除而直接辅助放疗。
研究设计与样本
- 基于人群的队列研究,纳入2001至2011年转诊的10,863例pT1-T3、任何N、M0浸润性乳腺癌女性,均接受保乳手术和全乳放疗(伴或不伴boost)。
- 按切缘状态分组:阴性(≥2 mm,n=9241,85%)、close(<2 mm,n=1310,12%)、阳性(肿瘤触及墨迹,n=312,3%),采用竞争风险分析、多因素分析和匹配配对分析。
主要发现
- 中位随访8年,全身治疗使用率87%,boost放疗在阴性、close和阳性切缘组分别为34.1%、76.9%和79.5%。
- 阴性、close和阳性切缘组的10年局部复发累积发生率分别为1.8%、2.0%和1.1%(P=.759),BCSS分别为93.9%、91.8%和87.9%(P<.001)。
- 多因素分析中close切缘与阴性切缘相比局部复发风险比为1.25(95%CI 0.79-1.97,P=.350),BCSS风险比为1.25(95%CI 0.98-1.58,P=.071)。
- 匹配配对分析中close切缘与阴性切缘的局部复发(P=.114)和BCSS(P=.100)相似。
关键数值与推荐
- 2014年SSO-ASTRO共识建议「肿瘤无墨迹」为浸润性乳腺癌保乳手术的充分切缘。
- 本研究中close切缘定义为<2 mm,阴性切缘定义为≥2 mm,阳性切缘定义为肿瘤触及墨迹。
临床怎么用
- 对于经仔细选择的close切缘(<2 mm)浸润性乳腺癌患者,可考虑不接受再次切除而直接进行辅助放疗。
- 该数据不支持对所有病例省略再次切除,close切缘病例仍需个体化选择。
局限性
- 原文未报告该研究的局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The 2014 Society of Surgical Oncology-American Society for Radiation Oncology consensus suggested "no ink on tumor" is a sufficient surgical margin for invasive breast cancer treated with breast-conserving surgery (BCS). Whether close margins <2 mm are associated with inferior outcomes remains controversial. This study evaluated 10-year outcomes by margin status in a population-based cohort treated with BCS and adjuvant radiation therapy (RT). METHODS AND MATERIALS: The subjects were 10,863 women with invasive cancer categorized as pT1 to T3, any N, and M0 referred from 2001 to 2011, an era in which the institutional policy was to re-excise close or positive margins, except in select cases. All women underwent BCS and whole-breast RT with or without boost RT. Local recurrence (LR) and breast cancer-specific survival (BCSS) were examined using competing-risk analysis in cohorts with negative (≥2 mm; n = 9241, 85%), close (<2 mm; n = 1310, 12%), or positive (tumor touching ink; n = 312, 3%) margins. Multivariable analysis and matched-pair analysis were performed. RESULTS: The median follow-up period was 8 years. Systemic therapy was used in 87% of patients. Boost RT was used in 34.1%, 76.9%, and 79.5% of patients with negative, close, and positive margins, respectively. In the negative, close, and positive margin cohorts, the 10-year cumulative incidence of LR was 1.8%, 2.0%, and 1.1%, respectively (P = .759). Corresponding BCSS estimates were 93.9%, 91.8%, and 87.9%, respectively (P < .001). On multivariable analysis, close margins were not associated with increased LR (hazard ratio, 1.25; 95% confidence interval 0.79-1.97; P = .350) or reduced BCSS (hazard ratio, 1.25; 95% confidence interval 0.98-1.58, P = .071) relative to negative margins. On matched-pair analysis, close margin cases had similar LR (P = .114) and BCSS (P = .100) to negative margin controls. CONCLUSIONS: Select cases with close or positive margins in this population-based analysis had similar LR and BCSS to cases with negative margins. While these findings do not endorse omitting re-excision for all cases, the data support a policy of accepting carefully selected cases with close margins for adjuvant RT without re-excision.
引用
- Tyler S, Truong PT, Lesperance M, et al. Close Margins Less Than 2 mm Are Not Associated With Higher Risks of 10-Year Local Recurrence and Breast Cancer Mortality Compared With Negative Margins in Women Treated With Breast-Conserving Therapy. Int J Radiat Oncol Biol Phys. 2018. PMID: 29678525. doi:10.1016/j.ijrobp.2018.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。